Genmab — Januar 2022
-
Daratumumab plus lenalidomide and dexamethasone : frailty subgroup analysis of MAIA https://www.nature.com/articles/s41375-021-01488-8
-
After >3 years of follow-up, D-Rd demonstrated improved efficacy versus Rd in transplant-ineligible NDMM patients, regardless of frailty status. These findings support the clinical benefit of D-Rd in transplant-ineligible NDMM patients enrolled in MAIA, regardless of frailty status.
-
Genmab/Guggenheim: Anbefaling sænkes til "neutral" fra "køb"
12:51
Genmab får sænket sin anbefaling til "neutral" fra "køb" af finanshuset Guggenheim.Det skriver Bloomberg News.
Det fremgår ikke, om kursmålet er ændret. Det seneste kursmål fra 14. december lød på 3087 kr.
Genmab-aktien falder mandag 0,6 pct. til 2614 kr.
.\˙ MarketWire
-
Genmab/Guggenheim: Anbefaling sænkes til "neutral" fra "køb" https://proinvestor.com/investornyt/758076/genmab-guggenheim-anbefaling-saenkes-til-neutral-fra-kob
-
Genmab to Present at the 40th Annual J.P. Morgan Healthcare Conference https://proinvestor.com/investornyt/758085/genmab-to-present-at-the-40th-annual-jp-morgan-healthcare-conference
-
Mandagens aktier: Investoroptimisme sendte C25 i plus - Mærsk i rekord https://www.proinvestor.com/investornyt/758211/mandagens-aktier-investoroptimisme-sendte-c25-i-plus-maersk-i-rekord
-
Jeg mener at partnerne i voldgiftsagen valgte voldgiftretten med virkning af begge partnere ville rette sig efter voldgiftretten afgørelse for at få en HURTIG afgørelse. Nu har sagen ligget i 12 - 18 mdr. - jeg mener det var i okt. 20 sagen kom frem - det er godt nok lang tid at vente på en afgørelse ..... Vi må håbe at afgørelsen falder her i 1. kvt. 22 .....
-
DuoHexaBody-CD37 trial adding a new arm; guess which one
https://www.clinicaltrials.gov/ct2/history/NCT04358458?A=7&B=8&C=merged#StudyPageTop -
Da sagen kom fremgooglede jeg lidt og fandt frem til, at det er helt almindelugt med med 18-20 måneder. Fordelene er ikke så meget hastigheden, men snarere fortroligheden, fleksibiliteten og den internationale anerkendelse af afgørelsen (versus en national domstol).
-
Gugenheim har simpelthen fjernet kursmålet.. iflg. Seeking Alpha: "Genmab (GMAB -0.3%) was downgraded by Guggenheim to Neutral from Buy and the price target on the stock was removed." https://seekingalpha.com/news/3784671-genmab-cut-to-neutral-at-guggenheim
-
-
"Guggenheim analyst Michael Schmidt said the company has developed "one of the leading monoclonal antibody technology platforms," and built a strong foundation of cash flows derived from royalties of out-licensed "blockbuster" products, but its success rate within the "proprietary" antibody pipeline has been only modest since he launched coverage."
-
Og ".. but its success rate within the "proprietary" antibody pipeline has been only modest since he launched coverage.".. ved ikke hvornår han startede sin dækning, men de sidste par år har da budt på adskillige lovende molekyler i klinikken. Hvad fanden er det han vil ha' - et par blockbustere om året?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind